Priyadharshini Ramakrishnan
Research Subjects
Priyadharshini Ramakrishnan has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Pavan Kumar Tupakula
Department of Oral Medicine and Radiology, Faculty of Dental Sciences, M.S. Ramaiah University of Applied Sciences, Bengaluru, India
3 shared publications - Sujatha Sampige Reddy
Department of Oral Medicine and Radiology, Faculty of Dental Sciences, M.S. Ramaiah University of Applied Sciences, Bengaluru, India
2 shared publications - V. Shwetha
Department of Oral Medicine, Radiology, Faculty of Dental Sciences, Ramaiah University of Applied Sciences, India
2 shared publications Alyssa Chen
1 shared publication- Amin Sharifan
Department for Evidence-based Medicine and Evaluation, University for Continuing Education Krems, Krems an der Donau, Austria
1 shared publication Bryn Longcroft-Harris
Faculty of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
1 shared publication
Latest Publications
- 23 September 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (12) , 2089-2091
Changing face of healthcare: digital therapeutics in the management of diabetes
Diagnosis, prevention, management and treatment of acute and chronic medical conditions have improved with technological advancements in terms of scalability, efficacy, access, and personalized approach. Digital therapeutic applications (DTx) (Blue Star®, Diabeo® System, Livongo Diabetes Program, Tidepool etc.,) use web-based applications/cloud platforms to provide evidence-based, personalized, rapid point of care management of chronic, behavior-modifiable conditions, including diabetes mellitus (DM). DTx has improved patient compliance, therapeutic success and economic outcomes in DM management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Addressing concerns along DTx data vulnerability, comparative efficacy with conventional treatments, ability to accommodate diverse population needs, and resolving ambiguous regulatory policies and reimbursement guidelines are critical for increasing access to DTx, and overcoming availability, accessibility, and affordability issues in the existing resource limited healthcare environment. In this commentary the authors explore the potential, prospects, and challenges of DTx in the management of Diabetes Mellitus.
- 23 September 2021
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 37 (12) , 2089-2091
Changing face of healthcare: digital therapeutics in the management of diabetes
Diagnosis, prevention, management and treatment of acute and chronic medical conditions have improved with technological advancements in terms of scalability, efficacy, access, and personalized approach. Digital therapeutic applications (DTx) (Blue Star®, Diabeo® System, Livongo Diabetes Program, Tidepool etc.,) use web-based applications/cloud platforms to provide evidence-based, personalized, rapid point of care management of chronic, behavior-modifiable conditions, including diabetes mellitus (DM). DTx has improved patient compliance, therapeutic success and economic outcomes in DM management by enabling active patient engagement, lifestyle change, comprehensive medical care, and periodic monitoring of glycemic status. Addressing concerns along DTx data vulnerability, comparative efficacy with conventional treatments, ability to accommodate diverse population needs, and resolving ambiguous regulatory policies and reimbursement guidelines are critical for increasing access to DTx, and overcoming availability, accessibility, and affordability issues in the existing resource limited healthcare environment. In this commentary the authors explore the potential, prospects, and challenges of DTx in the management of Diabetes Mellitus.
- 1 March 2021
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 33 (2) , 221-226
Methylation status of p16INK4a and p14ARF gene in saliva of smokeless tobacco users: A pilot descriptive study
- 1 March 2021
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 33 (2) , 221-226
Methylation status of p16INK4a and p14ARF gene in saliva of smokeless tobacco users: A pilot descriptive study
- 8 September 2020
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 49 (9) , 926-932
In silico evaluation of drugs used in treatment of oral lichen planus
Background: Oral lichen planus (OLP) is a chronic T cell–mediated, immunological, mucocutaneous disease with a number of genes and inflammatory mediators implicated in its pathogenesis. Heart shock protein 70 and the proinflammatory mediator TNFα have been predominantly involved in the etiopathogenesis of oral lichen planus.Methods: In this study, the action of 27 commonly used drugs for treating OLP at HSP70 and TNFα were evaluated by molecular docking using Maestro Schrodinger version 10.1. X‐ray crystallographic structures of the target proteins, that is, Heat Shock Protein 70 (PDB Code: 6FDT) and tumor necrosis factor alpha‐1 (PDB Code: 1TNF) were obtained from Protein Data Bank (PDB). The structures of the ligands (27 drugs) were obtained from PubChem in.sdf format. Using Ligprep, pre‐processing of the ligands was done. Extra‐precision docking was performed with the prepared protein and the ligands.Results: With respect to HSP70, the highest dock score (−4.768) and glide score (−4.818) were seen with hydroxychloroquine (HCQ), followed by epigallocatechin gallate (green tea), methotrexate, and curcumin. The highest dock (−9.525) and glide score (−9.584) in TNFα were seen in with epigallocatechin gallate, followed by HCQ, dapsone, and methotrexate.Conclusion: The results of the study tend to explain the clinical use of HCQ in recalcitrant and severe cases, as well as the anti‐inflammatory property of epigallocatechin gallate. The results of the study open ventures for exploring the in silico behavior of drugs for effective pathological management.
- 8 September 2020
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 49 (9) , 926-932
In silico evaluation of drugs used in treatment of oral lichen planus
Background: Oral lichen planus (OLP) is a chronic T cell–mediated, immunological, mucocutaneous disease with a number of genes and inflammatory mediators implicated in its pathogenesis. Heart shock protein 70 and the proinflammatory mediator TNFα have been predominantly involved in the etiopathogenesis of oral lichen planus.Methods: In this study, the action of 27 commonly used drugs for treating OLP at HSP70 and TNFα were evaluated by molecular docking using Maestro Schrodinger version 10.1. X‐ray crystallographic structures of the target proteins, that is, Heat Shock Protein 70 (PDB Code: 6FDT) and tumor necrosis factor alpha‐1 (PDB Code: 1TNF) were obtained from Protein Data Bank (PDB). The structures of the ligands (27 drugs) were obtained from PubChem in.sdf format. Using Ligprep, pre‐processing of the ligands was done. Extra‐precision docking was performed with the prepared protein and the ligands.Results: With respect to HSP70, the highest dock score (−4.768) and glide score (−4.818) were seen with hydroxychloroquine (HCQ), followed by epigallocatechin gallate (green tea), methotrexate, and curcumin. The highest dock (−9.525) and glide score (−9.584) in TNFα were seen in with epigallocatechin gallate, followed by HCQ, dapsone, and methotrexate.Conclusion: The results of the study tend to explain the clinical use of HCQ in recalcitrant and severe cases, as well as the anti‐inflammatory property of epigallocatechin gallate. The results of the study open ventures for exploring the in silico behavior of drugs for effective pathological management.
- 1 December 2019
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 120 (6) , 588-590
Association of OLP and thyroid disorder: Case report and review of literature
- 1 December 2019
- Published by Elsevier in Journal of Stomatology Oral and Maxillofacial Surgery
- Vol. 120 (6) , 588-590
Association of OLP and thyroid disorder: Case report and review of literature
- 1 April 2019
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 9 (2) , 215-220
Spectrum of features in Darier’s disease: A case report with emphasis on differential diagnosis
- 1 April 2019
- Published by Elsevier in Journal of Oral Biology and Craniofacial Research
- Vol. 9 (2) , 215-220
Spectrum of features in Darier’s disease: A case report with emphasis on differential diagnosis
- 22 May 2018
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 7 (6) , 1052-1056
Cure from the rhizomes: the medicine behind the Indian saffron Curcumin
Indian system of medicine has always focused on cure from the nature. Plant products from the Indian household have been used as medicine to cure myriad of ailments since ancestral times. Curcumin is a polyphenol, an active ingredient found in turmeric. In Southeast Asia, turmeric has been used as a coloring, flavoring and as a therapeutic agent. The use of turmeric to treat ailments dates back to the times of Charaka and Shushrutha. It has been widely used as an antiseptic for cuts, burns, and bruises, and as an antibacterial agent. Modern medicine has begun to understand its importance in recent times. Unfortunately its poor solubility, limited absorption and enhanced metabolism limits its bioavailability for its extended therapeutic use. Integration of nanotechnology in drug design and development has led the way to development of nanocurcumin with improved pharmacological properties. A precise understanding of effective dose, safety, and mechanism of action is required for the rational use of turmeric in the treatment of human diseases. This review focuses on the molecular actions of curcumin and its possibility to be used as a therapeutic agent in conditions affecting oral mucosa.
- 22 May 2018
- Published by Medip Academy in International Journal of Basic & Clinical Pharmacology
- Vol. 7 (6) , 1052-1056
Cure from the rhizomes: the medicine behind the Indian saffron Curcumin
Indian system of medicine has always focused on cure from the nature. Plant products from the Indian household have been used as medicine to cure myriad of ailments since ancestral times. Curcumin is a polyphenol, an active ingredient found in turmeric. In Southeast Asia, turmeric has been used as a coloring, flavoring and as a therapeutic agent. The use of turmeric to treat ailments dates back to the times of Charaka and Shushrutha. It has been widely used as an antiseptic for cuts, burns, and bruises, and as an antibacterial agent. Modern medicine has begun to understand its importance in recent times. Unfortunately its poor solubility, limited absorption and enhanced metabolism limits its bioavailability for its extended therapeutic use. Integration of nanotechnology in drug design and development has led the way to development of nanocurcumin with improved pharmacological properties. A precise understanding of effective dose, safety, and mechanism of action is required for the rational use of turmeric in the treatment of human diseases. This review focuses on the molecular actions of curcumin and its possibility to be used as a therapeutic agent in conditions affecting oral mucosa.